NCT00101426View on ClinicalTrials.gov

Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

September 30, 2006

Conditions
Diabetic Neuropathy
Interventions
DRUG

ranirestat, (AS-3201)

Trial Locations (1)

M5G 2C4

Toronto General Hospital, University Health Network, Toronto

All Listed Sponsors
lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT00101426 - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy | Biotech Hunter | Biotech Hunter